ストックスクリーナーアプリを入手
2.61
2.97%
-0.08
アフターアワーズ：
2.64
0.03
+1.15%
前日終値:
$2.69
開ける：
$2.768
24時間の取引高:
1.16M
Relative Volume:
0.41
時価総額：
$487.13M
収益：
$7.12M
当期純損益:
$-24.17M
株価収益率:
-10.72
EPS:
-0.2434
ネットキャッシュフロー:
$-41.95M
1週間 パフォーマンス:
-4.04%
1か月 パフォーマンス:
+8.75%
6か月 パフォーマンス:
+48.30%
1年 パフォーマンス:
+671.28%
1日の値動き範囲:
$2.595
$2.768
1週間の範囲:
$2.595
$2.835
52週間の値動き範囲:
$0.3305
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
名前
Ovid Therapeutics Inc
セクター
電話
212-776-4381
住所
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.61 | 502.06M | 7.12M | -24.17M | -41.95M | -0.2434 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-11 | 開始されました | Roth Capital | Buy |
| 2025-11-17 | 開始されました | Leerink Partners | Outperform |
| 2025-10-09 | 開始されました | Oppenheimer | Outperform |
| 2025-08-08 | 再開されました | B. Riley Securities | Buy |
| 2024-06-18 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 開始されました | B. Riley Securities | Buy |
| 2024-04-29 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-05 | 開始されました | Wedbush | Outperform |
| 2023-12-21 | 開始されました | BTIG Research | Buy |
| 2023-10-13 | 開始されました | Oppenheimer | Outperform |
| 2021-04-20 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-02 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-04-20 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Ovid Therapeutics Inc (OVID) 最新ニュース
Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Value Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Microcap Value Benchmark Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell Microcap Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000 Value Benchmark - marketscreener.com
Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ovid Therapeutics Inc. Actuals & Estimates (NASDAQ:OVID) - TradingView
OVID Forecast — Price Target — Prediction for 2027 - TradingView
AQST Stock Price and Chart — NASDAQ:AQST - TradingView
1OT Forecast — Price Target — Prediction for 2027 - TradingView
Ovid Therapeutics Inc. Actuals & Estimates (SWB:1OT) - TradingView
Price to earnings forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Price to sales forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - Sahm
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index - marketscreener.com
OVIDOvid Therapeutics Inc Latest SEC Filings - Finviz
Ovid Therapeutics (NASDAQ: OVID) grants director Anna Greka 130,000 stock options - Stock Titan
Ovid Therapeutics (OVID) director files initial Form 3 - Stock Titan
Ovid Therapeutics Inc (OVID) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Institutional Confidence - TradingKey
Ovid Therapeutics Inc (OVID) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ovid Therapeutics Inc (OVID) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ovid Therapeutics Inc (OVID) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ovid Therapeutics Inc (OVID) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OVID: Multiple clinical milestones and strong financial runway position the pipeline for significant value creation - TradingView
Ovid Therapeutics Shareholders Back Board and Governance Proposals - The Globe and Mail
Ovid Therapeutics (OVID) Slips 1.97% as Shares Test Key Support LevelsStrong Buy Stocks - newsline.com
Ovid Therapeutics (NASDAQ: OVID) shareholders approve director, pay and auditor - Stock Titan
Ovid Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Ovid Board Move Puts Scientific Strategy Back In Focus - Kalkine Media
Ovid Therapeutics Expands Board, Appoints New Scientific Director - The Globe and Mail
Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Ovid Therapeutics appoints Anna Greka to board of directors - Investing.com UK
Ovid Therapeutics appoints Anna Greka to board of directors By Investing.com - Investing.com Canada
Anna Greka joins Ovid Therapeutics (NASDAQ: OVID) board, expanding it to seven - Stock Titan
Ovid Therapeutics Appoints Leading Physician-Scientist and - GlobeNewswire
Ovid Therapeutics (OVID) Edges Higher: Key Levels in FocusVolume Climax - dars.gov.et
Ovid Therapeutics (OVID) Gains Nearly 4% as Shares Test Key ResistanceUnusual Put Volume - newsline.com
Will Ovid’s golden age of KCC2 metamorph CNS? - BioWorld News
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4 - Moomoo
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Point72 (OVID) discloses shared 1.3% position, including warrants - Stock Titan
Eventide (OVID) discloses 12.8M-share, 7.3% position in Ovid Therapeutics - Stock Titan
Ovid Therapeutics (OVID) Schedule 13G: Sirenia/manager report 9.9% stake - Stock Titan
Ovid Therapeutics Inc (OVID) 財務データ
収益
当期純利益
現金流量
EPS
Ovid Therapeutics Inc (OVID) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ALEXANDER MARGARET A. | President and CEO |
Feb 23 '26 |
Sale |
1.45 |
11,656 |
16,901 |
61,750 |
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
0.05%
0.74%
大文字化:
|
ボリューム (24 時間):